By PPN News Staff
The FDA today approved the orphan drug, deflazacort (Emflaza, Marathon Pharmaceuticals) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness.